Last reviewed · How we verify
Caprylic Acid (OCTANOIC ACID)
Caprylic Acid (generic name: OCTANOIC ACID) is a octanoic acid drug. It is currently in Phase 2 development.
Caprylic Acid works by binding to the G-protein coupled receptor 84, which is involved in various cellular processes.
Caprylic acid is used in the formulation of Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified, which is being studied for the treatment of various immunodeficiency conditions, including Immunologic Deficiency Syndrome, Agammaglobulinemia, and Common Variable Immunodeficiency. The exact mechanism of caprylic acid in this context is not specified in the provided information, but it is used as a component of the immune globulin formulation.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | OCTANOIC ACID |
|---|---|
| Drug class | octanoic acid |
| Target | G-protein coupled receptor 84 |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your cells have locks on them, and the key to unlocking these locks is a specific molecule that fits perfectly. Caprylic Acid is like a key that fits into one of these locks, allowing it to influence the behavior of the cell. This can lead to changes in how the cell functions, which may be beneficial in treating certain diseases.
Approved indications
Common side effects
Key clinical trials
- 13C-Octanoic Acid Breath Test on Gastric Emptying in Celiac Patients With Functional Disorders (NA)
- Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK (PHASE2)
- Effect of Topical Agents With Various Antioxidant Containts on Photodamage Skin Induced (PHASE2)
- A Multiple-Dose Study of LY3493269 in Healthy Participants (PHASE1)
- A Study of LY3493269 in Healthy Participants (PHASE1)
- Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (PHASE1,PHASE2)
- CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy (PHASE2)
- CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Caprylic Acid CI brief — competitive landscape report
- Caprylic Acid updates RSS · CI watch RSS
Frequently asked questions about Caprylic Acid
What is Caprylic Acid?
How does Caprylic Acid work?
What is the generic name of Caprylic Acid?
What drug class is Caprylic Acid in?
What development phase is Caprylic Acid in?
What does Caprylic Acid target?
Related
- Drug class: All octanoic acid drugs
- Target: All drugs targeting G-protein coupled receptor 84
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing